Objective-The objective of this trial was to study the effects of fenofibrate (FF) and gemfibrozil (GF), the most commonly used fibrates, on high-density lipoprotein (HDL) and apolipoprotein (apo) A-I. Methods and Results-In a head-to-head double-blind clinical trial, both FF and GF decreased triglycerides and increased HDL cholesterol levels to a similar extent, whereas plasma apoA-I only increased after FF but not GF. Results in human (h) apoA-Itransgenic (hA-ITg) peroxisome proliferator-activated receptor (PPAR) ␣Ϫ/Ϫ mice demonstrated that PPAR␣ mediates the effects of FF and GF on HDL in vivo. Although plasma and hepatic mRNA levels of hapoA-I increased more pronouncedly after FF than GF in hA-ITgPPAR␣ϩ/ϩ mice, both fibrates induced acylCoAoxidase mRNA similarly. FF and GF transactivated PPAR␣ with similar activity and affinity on a DR-1 PPAR response element, but maximal activation on the hapoA-I DR-2 PPAR response element was significantly lower for GF than for FF. Moreover, GF induced recruitment of the coactivator DRIP205 on the DR-2 site less efficiently than did FF. Conclusion-Both GF and FF exert their effects on HDL through PPAR␣. Whereas FF behaves as a full agonist, GF appears to act as a partial agonist due to a differential recruitment of coactivators to the promoter. These observations provide an explanation for the differences in the activity of these fibrates on apoA-I. (Arterioscler Thromb Vasc Biol. 2005;25:585-591.)
S everal clinical trials have indicated a benefit of fibrate treatment in cardiovascular risk reduction and improvement of lipid profiles. 1 Angiography trials have shown that administration of fibrates (bezafibrate, gemfibrozil [GF], and fenofibrate [FF]) significantly decreases the progression of coronary narrowing. 1 Furthermore, fibrate treatment decreased combined incidence of coronary heart disease events in primary and secondary prevention trials. 1 These trials also demonstrated the effectiveness of fibrates in improving dyslipidemia by lowering elevated plasma triglycerides, improving the low-density lipoprotein subfraction distribution, and increasing high-density lipoprotein cholesterol (HDL-C). However, qualitative and quantitative differences appear to exist between fibrates. Qualitative differences in pharmacological modulation of HDL metabolism, and its major apolipoprotein (apo) A-I that confers protection against the development of atherosclerosis in animal models 2 and humans, 3 may be of clinical importance. In several clinical trials, FF increases plasma HDL-C and apoA-I concentrations. 4 -8 By contrast, although significantly increasing HDL-C levels, GF seems to have little or no effect on apoA-I levels. 9 -11 Thus, the 2 most used fibrates (FF and GF), although exerting similar beneficial actions on plasma lipids, may also exert distinct effects by yet unresolved mechanisms.
Even though fibrates are low-affinity ligands, their effects are thought to be mediated principally through peroxisome proliferator-activated receptor (PPAR) ␣. Fibrate-activated PPAR␣ regulates gene expression after heterodimerization with the retinoid X receptor (RXR), subsequent coactivator recruitment, and binding to PPAR response elements (PPREs) which are located in target gene promoters. The PPAR/RXR heterodimer interacts with coactivators that act as bridges with the basal transcription machinery and play crucial roles in the transmission of regulatory signals. Differ-ent ligands can induce different receptor conformations in a way that is unique to each ligand, leading to differential coactivator recruitment. This is the case for PPAR␥ agonists. Compared with other glitazones, troglitazone behaves as a partial or full agonist for PPAR␥ depending on the cellular environment and promoter context leading to PPAR␥ selective modulation and differential downstream effects on gene expression. 12 This selective PPAR modulator concept may explain differences in biological activity.
In this study the clinical effects of FF and GF were compared on lipid metabolism with a focus on their effects on HDL and apoA-I in a head-to-head trial. Moreover, the molecular mechanisms underlying observed differences were investigated.
Methods

Clinical Study
A multicenter, double-blind, randomized, 24-week study was performed comparing head-to-head the usual doses of micronized FF (200 mg per day) and GF (1200 mg per day). After an 8-week placebo run-in period, 234 patients (82 women, 152 men) aged 18 to 70 years (mean age 51.6 years) with combined hyperlipidemia (total cholesterol [TC]/HDL-C Ն6.0 mmol/L [males], Ն5.6 mmol/L [females]; triglycerides between 2.2 and 5.6 mmol/L) were randomized and treated with FF (nϭ116) or GF (nϭ118). Both drugs were equally well tolerated. For triglyceride, HDL-C, and apoA-I measurement, please see the online Methods, available at http://atvb.ahajournals.org.
Comparison of percent changes was done by 1-way analysis of variance. The study was approved by the independent ethics committee of each of the 10 participating Canadian centers.
Animals
Hemizygous hA-ITg mice on a PPAR␣Ϫ/Ϫ, ϩ/Ϫ, and ϩ/ϩ background were obtained by crossing homozygous human (h) apoA-Itransgenic (hA-ITg) mice 13 with PPAR␣-null mice 14, 15 and subsequently treated with either FF or GF (0.2 and 0.5% w/w, respectively) for 17 days, a time at which a steady-state response is reached 16 (see online Methods). All animal experiments were approved by the Institutional Animal Care and Use Committee.
Lipid, Apolipoprotein, and Lipoprotein Analyses
Plasma TC was determined as described. 15 Plasma human (h) apoA-I and mouse apoA-II levels were measured by an immunonephelometric assay using species-specific antibodies. 17 Lipoprotein cholesterol distribution in pooled plasma samples was assessed by fast protein liquid. 18 hapoA-I was measured in each eluted fraction using the same immunonephelometric assay as above, 17 and HDL fractions were defined as apoA-I containing fractions. HDL-C was determined from the cholesterol distribution profiles by calculating the areas under the curves of the apoA-I-containing fractions.
RNA Analysis
RNA was isolated and Northern blot analysis was performed as described 19 using hapoA-I and rat acylCoAoxidase (ACO) probes and human ribosomal 28S cDNA as a control probe. hapoA-I, ACO, and mouse apoA-II levels were quantified by reverse transcription followed by real-time polymerase chain reaction, normalized to the 28S internal control, and expressed as fold induction over the untreated control group, set as 1 (see online Methods).
Statistical Analysis
ANOVA was used to compare differences between treatment groups. When overall significance was attained, Scheffe test was used to analyze for significant differences between the experimental groups.
Transient Transfection Assays
The pSG5-mPPAR␣ plasmid was as described. 20 The hapoA-II-DR-1 (J6-TK-Luc) and hapoA-I-DR-2 (A3-TK-pGL3)-containing reporter plasmids were obtained by inserting 6 or 3 copies of the hapoA-II PPRE (DR-1)-containing J or the hapoA-I PPRE (A site) 21 sites in the pTK-pGL3 plasmid, respectively (see online Methods).
Cos-7 cells were transfected using polyethylenimine before the addition of increasing concentrations of the compound tested or vehicle for 24 hours in 0.2% FCS-DMEM (see online Methods). The pCMV-␤-galactosidase expression plasmid was cotransfected as a control for transfection efficiency. Luciferase and ␤-galactosidase assays were performed as described. 22 EC 50 values were estimated using Prism software(GraphPad).
Cofactor Recruitment Assays
The glutathione-S-transferase pull-down protocol was as described. 23 DNA-dependent protein-protein interactions were tested as described previously. 24 Briefly, hPPAR␣ and 35 S-labeled-hRXR␣ were incubated with or without PPAR␣ ligand before a doublestranded oligonucleotide corresponding to the ACO or hapoA-I PPRE and glutathione-S-transferase-DRIP205 were added (see online Methods). Complexes were resolved and quantified with a PhosphorImager (Molecular Dynamics).
Results
FF and GF Regulate ApoA-I Differently in Humans
To compare the effects of FF and GF on plasma lipids and apoA-I, 234 patients with combined hyperlipidemia were treated with FF (nϭ116) or GF (nϭ118) in a head-to-head, double-blind, randomized trial. Baseline characteristics of patients are given in Table I (available online at http://atvb.ahajournals.org).
Both fibrates reduced triglycerides (FF, Ϫ39Ϯ22% versus GF, Ϫ41Ϯ26%, PϾ0.5) and increased HDL-C (FF, ϩ16Ϯ20% versus GF, ϩ12Ϯ21%, PϾ0.5) to a similar extent ( Figure 1 ). Interestingly, although having similar HDL-C increasing activities, only FF treatment increased apoA-I plasma levels, whereas GF treatment was without effect (FF, ϩ8.6Ϯ14% versus GF, ϩ1.5Ϯ12%, PϽ0.001; Figure 1 ).
PPAR␣ Mediates the Effects of FF on Plasma HDL-C and hapoA-I Plasma and Hepatic mRNA Levels In Vivo in Mice
To determine the mechanistic basis of this differential effect, we first aimed to establish whether PPAR␣ is required for the in vivo regulation of HDL-C and hapoA-I levels by fibrates. hapoA-I-transgenic (hA-ITg) mice on a PPAR␣ϩ/ϩ, ϩ/Ϫ, and Ϫ/Ϫ background were treated with FF for 17 days. In PPAR␣ϩ/ϩhA-ITg mice, FF treatment resulted in significant Ϸ4and 3.5-fold increases of plasma TC and hapoA-I levels (TC: control [CON], 159Ϯ9 versus FF, 618Ϯ31 mg/dL, PϽ0.001; hapoA-I: CON, 411Ϯ13 versus FF,1503Ϯ117 mg/dL, PϽ0.001). By contrast, no increase was observed in the PPAR␣Ϫ/ϪhA-ITg mice (TC: CON, 152Ϯ8 versus FF, 108Ϯ7 mg/dL, PϾ0.05; hapoA-I: CON, 315Ϯ19 versus FF, 268Ϯ8 mg/dL, PϾ0.05; Figure 2A and 2B). Strikingly, treatment with FF increased TC (CON, 145Ϯ9 versus FF, 328Ϯ29 mg/dL, PϽ0.001) and hapoA-I (CON, 322Ϯ20 versus FF, 625Ϯ51 mg/dL, PϽ0.05) to intermediate levels in PPAR␣ϩ/ϪhA-ITg mice compared with PPAR␣ϩ/ϩ and PPAR␣Ϫ/Ϫ mice (Figure 2A and 2B ). Consistently, changes in HDL-C distribution profiles in the PPAR␣ϩ/ϪhA-ITg mice occurred in an intermediate fashion when compared with the 2 other PPAR␣ genotypes (data not shown). In agreement with the above results, FF treatment induced a marked increase in hepatic hapoA-I mRNA levels in the PPAR␣ϩ/ϩhA-ITg mice (CON, 100Ϯ15 versus FF, 226Ϯ10%, PϽ0.001), whereas no effect was observed in the PPAR␣Ϫ/ϪhA-ITg mice (CON, 100Ϯ20 versus FF, 121Ϯ8%, PϾ0.05; Figure I , available online at http://atvb. ahajournals.org), and an intermediate effect was observed in the PPAR␣ϩ/ϪhA-ITg mice (CON, 100Ϯ7 versus FF, 173Ϯ25%, PϽ0.01). Altogether these data indicate that the increase of HDL-C and hapoA-I plasma and hepatic mRNA levels by FF in hA-ITg mice occurs in a PPAR␣ gene dosage-dependent manner.
FF and GF Exert Distinct PPAR␣-Dependent Effects on HDL-C and hapoA-I Plasma Levels in Mice
The effect of FF and GF on the in vivo regulation of HDL-C and hapoA-I was next assessed in hA-ITgPPAR␣ϩ/ϩ and PPAR␣Ϫ/Ϫmice. FF and, albeit to a lower extent, GF significantly increased plasma TC in PPAR␣ϩ/ϩhA-ITg mice (CON, 158Ϯ7 versus FF, 498Ϯ31 mg/dL, PϽ0.001; CON, 158Ϯ7 versus GF, 224Ϯ13 mg/dL, PϽ0.01; Figure  3A ), whereas this effect was not observed in the PPAR␣Ϫ/Ϫ background ( Figure II , available online at http://atvb. ahajournals.org). A large increase in HDL-C was observed in PPAR␣ϩ/ϩhA-ITg mice treated with FF and GF, although the effect of GF was again less pronounced compared with FF (Ϸ1.6-fold versus Ϸ3.5-fold, respectively; Figure 3B ). No change was observed in the PPAR␣Ϫ/ϪhA-ITg mice ( Figure  II ). Furthermore, FF and GF treatment led to the appearance of a larger peak overlapping the low-density lipoprotein and HDL size range in a PPAR␣-dependent manner.
FF increased plasma hapoA-I in PPAR␣ϩ/ϩhA-ITg mice (CON, 357Ϯ12 versus FF, 886Ϯ181 mg/dL, PϽ0.001; Figure 3A) , an effect that was not observed in the PPAR␣Ϫ/Ϫ background (CON, 304Ϯ20 versus FF, 253Ϯ8 mg/dL, PϾ0.05). In contrast to FF, plasma hapoA-I levels were only slightly modified by GF treatment in the PPAR␣ϩ/ϩhA-ITg mice (CON, 357Ϯ12 versus GF, 394Ϯ12 mg/dL, PϾ0.05; Figure 3A ). Altogether these data demonstrate that both GF and FF induce HDL-C levels in a PPAR␣-dependent manner. However, in contrast to FF, GF has only a marginal effect on plasma hapoA-I.
FF Induces hapoA-I to a Larger Extent Than GF, Whereas Both Fibrates Increase ACO mRNA Levels Similarly in Mice
In line with the plasma changes, FF significantly increased hapoA-I mRNA levels in PPAR␣ϩ/ϩ mice (Figure 4 ) but was ineffective in the PPAR␣Ϫ/ϪhA-ITg mice. However, GF treatment was not efficient to induce hepatic hapoA-I mRNA levels in PPAR␣ϩ/ϩhA-ITg mice (Figure 4 ). By contrast, mRNA levels of ACO, a DR-1-driven PPAR␣ target gene, 25 were increased by GF treatment to a similar extent as FF (4.7-and 5.3-fold increase, respectively) in PPAR␣ϩ/ϩhA-ITg mice, whereas no change was observed with either treatment in the PPAR␣Ϫ/ϪhA-ITg mice ( Figure  4 ). Hepatic mRNA levels of mouse apoA-II, another important protein constituent of HDL, were also measured. Neither FF nor GF significantly affected mouse (m) apoA-II mRNA levels in PPAR␣ϩ/ϩhA-ITg mice (FF, 110Ϯ30%; GF, 121Ϯ28%; CON, 100Ϯ10%). However, both FF and GF treatment increased mapoA-II plasma levels in PPAR␣ϩ/ ϩhA-ITg mice (FF, 136Ϯ20%, PϽ0.01; GF, 200Ϯ65%, PϽ0.01; CON, 100Ϯ19%), whereas no change was observed with either FF or GF in the PPAR␣Ϫ/ϪhA-ITg mice (FF, 102Ϯ23%, PϾ0.05; GF, 128Ϯ18%, PϾ0.05; CON, 100Ϯ10%). Thus, GF appears to behave as a selective PPAR␣ modulator in vivo.
GF and FF Distinctly Induce PPAR␣ Activation and Coactivator Recruitment in a PPRE-Dependent Manner
The PPAR␣ activation profile of GF and FF was determined in a transfection assay in which full-length PPAR␣ was cotransfected with reporter constructs driven by either the hapoA-I DR-2 or a DR-1 PPRE (Figure 5A and 5B ). GF and FF increased PPAR␣ activity from the hapoA-I DR-2 site with similar EC 50 values (5.8 and 7.8 mol/L, respectively). However, a submaximal response was observed with GF compared with FF ( Figure 5A ). By contrast, on the DR-1 PPRE-driven vector, FF and GF activated PPAR␣ with similar EC 50 values (12 mol/L and 11 mol/L, respectively) and similar maximal response ( Figure 5B) . These data indi-cate that GF behaves as a partial agonist compared with FF depending on the type of PPRE. Next, the influence of FF and GF on coactivator recruitment to PPAR␣/RXR bound to either a DR-1 or the hapoA-I DR-2 site was examined. DRIP205 was chosen as a model system, but similar results were obtained with other coactivators, that is, p300, CBP (CREB binding protein), and glucocorticoid receptor interacting protein (data not shown). Compared with FF, GF led to at least as efficient coactivator recruitment to the DR-1 site but was comparatively less efficient on the hapoA-I DR-2 site ( Figure 5C and 5D ). Taken together, these findings suggest that GF selectively modulates PPAR␣ transcriptional activity associated with less efficient coactivator recruitment on the hapoA-I DR-2 site as compared with a DR-1 PPRE.
Discussion
Fibrates are useful drugs in the treatment of dyslipidemia characterized by elevated triglyceride and reduced HDL levels. Several clinical studies have demonstrated the efficacy of fibrate treatment to improve lipid profiles and in reducing the risk of coronary heart disease events. Even though no comparative studies were available, the 2 most widely used fibrates (FF and GF) appear to exert overlapping but distinct effects. Although both FF and GF increase plasma HDL-C, FF efficiently increases plasma apoA-I, 4 -7,26 whereas GF seems to have little or no effect on this parameter in humans. 9 -11,27 In this study, we assessed the effect of FF and GF on plasma lipids and apoA-I levels in hyperlipidemic patients. Both FF and GF induced a quantitatively comparable increase in HDL-C and decrease in triglyceride levels. Even though there was no significant difference in the change from baseline in HDL-C levels between FF and GF, a significant increase in apoA-I levels was seen only in FF-treated patients, whereas GF recipients displayed unchanged apoA-I levels from baseline. Although this is the first head-to-head comparison, our data are in line with results from several other clinical trials showing an increase of both HDL-C and hapoA-I concentrations after FF treatment. 4 -7 Furthermore, recent turnover studies have shown that FF treatment in humans significantly increases apoA-I plasma levels through enhancing its synthesis rate. 28, 29 By contrast, in the Veterans Affairs High-Density Lipoprotein Intervention Trial, GF treatment, although significantly increasing HDL-C levels, had no effect on apoA-I. 9 Similarly, in other trials GF also failed to increase apoA-I concentrations despite a significant increase in HDL-C levels. 10, 11, 27 Accordingly, the present report clearly establishes in a direct comparison that, although having similar effect on HDL-C levels, FF and GF differentially influence apoA-I levels in humans. By contrast, both FF and GF have been shown to induce apoA-II levels and LpA-I:A-II particles in patients, 27, 30 further emphasizing a selective increase of apoA-I by FF.
It was next determined whether PPAR␣ mediates fibrate action on HDL-C and hapoA-I in hA-ITgPPAR␣ϩ/ϩ and PPAR␣Ϫ/Ϫ mice. Humanized transgenic apoA-I mice were studied, because HDL metabolism is regulated in an opposite fashion by fibrates in rodents (decrease) and man (increase) due to sequence divergences in the respective apoA-I promoters. 21 FF and, albeit to a lesser extent, GF significantly increased plasma HDL-C levels in PPAR␣ϩ/ϩhA-ITg mice, whereas no change was observed in the PPAR␣Ϫ/ϪhA-ITg mice. In addition, and in line with the human situation, 30, 31 both FF and GF increased plasma apoA-II levels in mice in a PPAR␣-dependent manner, although no significant change in hepatic mapoA-II gene expression was observed. The appearance of larger HDL particles after fibrate treatment is likely because of increased expression of phospholipid transfer protein 18 and decreased scavenger receptor class B type I protein levels in liver. 32 It is noteworthy that quantitative differences exist between the 2 fibrates, because GF was less effective than was FF to increase HDL-C levels and change HDL size distribution.
Consistent with the observations in humans, FF treatment strongly increased hapoA-I plasma and hepatic mRNA levels in a PPAR␣-dependent manner. Similar results were obtained in ciprofibrate-treated mice (data not shown). Surprisingly, although GF administration to PPAR␣ϩ/ϩhA-ITg mice led to increased HDL-C levels, plasma apoA-I remained unchanged. Interestingly, GF treatment did not influence hepatic hapoA-I mRNA levels, whereas mRNA levels of ACO, a classical PPAR␣ target gene, 33 were increased to a similar extent by FF and GF. It is important to note that these fibrates were administered at doses and for a time period allowing maximal in vivo effectiveness in rodent. 16 Furthermore, the observed differences in apoA-I gene expression after GF and FF were not related to differences in the administered doses (0.2% FF versus 0.5% GF), because FF and GF induced ACO mRNA levels to a similar extent (ϫ5.3 versus ϫ4.7, respectively) indicating equipotent activity in the liver. Altogether, these data establish that PPAR␣ mediates both fibrate effects in our study and suggest that GF behaves as a selective modulator of PPAR␣ in vivo.
The ability of FF and GF to activate PPAR␣ was examined using a reporter vector driven by either a DR-1 or the apoA-I DR-2-type PPREs. FF fully induced PPAR␣ transactivation, whereas GF only elicited a partial transactivation on the hapoA-I DR-2 PPRE. Both GF and FF exhibited similar affinities for PPAR␣. By contrast, GF and FF were equally active on a DR-1-type PPRE. Detailed analysis has revealed that the binding of PPAR␣ to the hapoA-I promoter occurs through a DR-2-type PPRE within the A site, 34 whereas the ACO site is a DR-1 response element. 25 Our data show that GF behaves as a partial or full PPAR␣ agonist depending on the type of PPRE, whereas FF fully induces PPAR␣ transactivation activity on both DR-1 and DR-2 sites.
To understand the role of the PPRE structure in the distinct action of FF and GF, the ability of both ligands to induce coactivator recruitment to PPAR␣ on DR-1 versus DR-2 PPREs was compared. Our data indicate that GF is less efficient to induce DRIP205 recruitment to the PPAR␣/RXR heterodimer bound to the DR-2. By contrast, FF elicited similar recruitment efficiency to both types of complexes. This indicates that GF induces differential coactivator recruitment to the PPAR␣/RXR-DNA complex depending on the geometry of the PPRE. This is in line with previous reports showing that the nature of the response element plays a crucial role by inducing allosteric conformational changes of the receptor, leading to distinct coactivator recruitment, receptor activity, and gene response. 35 Whether DRIP205 is the coactivator explaining the different in vivo responses is impossible to answer. However, it can be concluded from our data that weaker coactivator recruitment to PPAR␣ by GF, because of distinct PPRE architecture, is likely to be the basis of the selective modulation of gene expression by GF in vivo.
Another important observation of this study is that PPAR␣ expression levels determine the response to fibrates. When treated with FF, PPAR␣ϩ/ϪhA-ITg mice showed an intermediate response with respect to plasma TC, HDL-C, and hapoA-I plasma and liver mRNA levels. Thus, our data provide genetic evidence that PPAR␣ expression levels determine the response to fibrates. Because we previously reported that human liver PPAR␣ levels vary Ͼ2-fold among individuals, 36 it is likely that in humans also the response to fibrate treatment will differ between individuals because of differences in PPAR␣ expression levels. In conclusion, this article strongly supports the fact that GF behaves as a selective PPAR␣ modulator in humans. It is interesting to note that GF is chemically different from other fibrates. 37 Although differences in pharmacokinetics and metabolism between fibrates may also contribute to distinct clinical phenotypes and even though GF may also have additional effects, 38 our data provide a plausible mechanism for the clinically observed differences between FF and GF. Our observations may have potential significant implications with regard to pharmacological effects of fibrates, and future studies may be aimed at identifying selective PPAR␣ modulators to improve therapeutic efficacy.
